SAN DIEGO – First-line treatment of peripheral T-cell lymphomas (PTCL) with a quartet of drugs substituting Adcetris (brentuximab vedotin) for Oncovin (vincristine) in the decades-old standard of care for the disease, CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), proved superior on both progression-free survival and overall survival, according to full data reported Tuesday by Seattle Genetics Inc. and partner Takeda Pharmaceutical Co. Ltd.